Advertisement: Mogrify mid banner
Mid banner advertisement: BDO
Advertisement: S-Tech mid banner 3
Advertisement: EY Mid banner
Advertisement: TTP
Advertisement: RSM
Advertisement: EBCam mid banner
ARM Innovation Hub
RealVNC mid banner careers
Advertisement: Cambridge Network mid banner
Advertisement: Howard Group mid banner
Advertisement: Hewitsons mid banner
Advertisement: Simpsons Creative
Advertisement: Wild Knight Vodka
Barr Ellison Solicitors – commercial property
Advertisement: Kao Data Centre mid banner
5 March, 2020 - 20:12 By Kate Sweeney

Italian pioneer works with TTP to boost global health diagnostics

Technology hothouse TTP is at the heart of a European initiative to revolutionise in vitro diagnostic medical device (IVD) technology to boost healthcare options.

Cambridge, UK consultancy TTP and DiaSorin, an Italian global leader in the IVD field, have signed an exclusive licence and technology transfer agreement to forge fresh frontiers.

DiaSorin will combine its extensive molecular test offering with TTP’s Puckdx™ platform to develop a single-use, sample-to-answer, molecular diagnostics point-of-care platform for human IVD applications.

TTP’s proprietary Puckdx platform offers a flexible, fast time-to-result and low-cost solution for translating diagnostic assays for human and animal health and life science research to an easy-to-use desktop device. 

Puckdx is based on a unique disposable robotic pipette system with a fast PCR module, combined with a cartridge containing all the necessary reagents.

Using this simple and cost-effective technology solution in combination with DiaSorin’s human IVD assays could provide clients with a result in less than 15 minutes.

This could help to decentralise testing, which in turn could make diagnostic services more affordable and convenient for patients and reduce the time from diagnosis to treatment to help prevent the spread of infectious diseases.


Giles Sanders, consultant at TTP plc

Giles Sanders, consultant at TTP plc said: “We are delighted that DiaSorin has chosen Puckdx as their preferred POC platform. We look forward to working in close partnership with DiaSorin to rapidly commercialise the platform, benefiting patients and healthcare providers worldwide.” 

Colleague Piers Harding added: “During the development of the Puckdx platform we have focused on a system that enables easy transfer of assays and a reliable and readily manufactured disposable.

“We are excited to have such a major diagnostic company wishing to bring the platform to market for human applications. The opportunity to utilise Puckdx for other fields of application continues to be available and we would be keen to collaborate with key players developing assays in areas such as for animal health and low-cost lab robotics.”

The Puckdx platform is based on a unique disposable robotic pipette system with a fast PCR module, combined with an easy-to-use cartridge containing all the necessary reagents.

Newsletter Subscription

Stay informed of the latest news and features